1932

Abstract

Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor–positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials—elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant—with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies. This review summarizes the currently available literature on this new class of drugs.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-052423-122001
2025-01-27
2025-02-07
Loading full text...

Full text loading...

/deliver/fulltext/med/76/1/annurev-med-052423-122001.html?itemId=/content/journals/10.1146/annurev-med-052423-122001&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Allemani C, Matsuda T, Carlo VD, et al. 2018.. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. . Lancet 391:(10125):102375
    [Google Scholar]
  2. 2.
    Zhai J, Wu Y, Ma F, et al. 2023.. Advances in medical treatment of breast cancer in 2022. . Cancer Innov. 2:(1):117
    [Google Scholar]
  3. 3.
    Dunnwald LK, Rossing MA, Li CI. 2007.. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. . Breast Cancer Res. 9::R6
    [Google Scholar]
  4. 4.
    Patel R, Klein P, Tiersten A, Sparano JA. 2023.. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. . NPJ Breast Cancer 9::20
    [Google Scholar]
  5. 5.
    Heldring N, Pike A, Andersson S, et al. 2007.. Estrogen receptors: How do they signal and what are their targets. . Physiol. Rev. 87:(3):90531
    [Google Scholar]
  6. 6.
    Hanker AB, Sudhan DR, Arteaga CL. 2020.. Overcoming endocrine resistance in breast cancer. . Cancer Cell 37:(4):496513
    [Google Scholar]
  7. 7.
    Cardoso F, Paluch-Shimon S, Senkus E, et al. 2020.. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). . Ann. Oncol. 31:(12):162349
    [Google Scholar]
  8. 8.
    Gnant M, Turner NC, Hernando C. 2023.. Managing a long and winding road: estrogen receptor–positive breast cancer. . Am. Soc. Clin. Oncol. Educ. Book 43::e390922
    [Google Scholar]
  9. 9.
    Osborne CK, Wakeling A, Nicholson RI. 2004.. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. . Br. J. Cancer 90:(Suppl. 1):S26
    [Google Scholar]
  10. 10.
    Robertson JFR, Harrison M. 2004.. Fulvestrant: pharmacokinetics and pharmacology. . Br. J. Cancer 90:(Suppl. 1):S710
    [Google Scholar]
  11. 11.
    Vilbert MS, Xavier DP, Cesca MG, et al. 2023.. 481P Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: a systematic review and meta-analysis of clinical trials. . Ann. Oncol. 34:(Suppl. 2):S383
    [Google Scholar]
  12. 12.
    Wardell SE, Ellis MJ, Alley HM, et al. 2015.. Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy–resistant breast cancer. . Clin. Cancer Res. 21:(22):512130
    [Google Scholar]
  13. 13.
    Bidard F-C, Kaklamani VG, Neven P, et al. 2022.. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. . J. Clin. Oncol. 40:(28):324656
    [Google Scholar]
  14. 14.
    Sanchez KG, Nangia JR, Schiff R, Rimawi MF. 2022.. Elacestrant and the promise of oral SERDs. . J. Clin. Oncol. 40:(28):322729
    [Google Scholar]
  15. 15.
    Bardia A, Bidard F-C, Neven P, et al. 2023.. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. . Cancer Res. 83:(5 Suppl.):GS3-01
    [Google Scholar]
  16. 16.
    Rugo H, Bardia A, Cortés J, et al. 2024.. Abstract PO2-05-04: ELEVATE: a phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). . Cancer Res. 84:(9 Suppl.):PO205-04
    [Google Scholar]
  17. 17.
    Ibrahim N, Kim S-B, Lin N, et al. 2024.. Abstract PO2-05-05: ELECTRA: an open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). . Cancer Res. 84:(9 Suppl.):PO205-05
    [Google Scholar]
  18. 18.
    Vidal M, Pascual T, Falato C, et al. 2023.. Abstract PD13-01: PD13-01 elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial. . Cancer Res. 83:(5 Suppl.):PD13-01
    [Google Scholar]
  19. 19.
    Oliveira M, Hamilton EP, Incorvati J, et al. 2022.. Serena-1: updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. . J. Clin. Oncol. 40:(16 Suppl.):1032
    [Google Scholar]
  20. 20.
    Turner N, Vaklavas C, Calvo E, et al. 2023.. Abstract P3-07-28: SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer. . Cancer Res. 83:(5 Suppl.):P307-28
    [Google Scholar]
  21. 21.
    Oliveira M, Pominchuck D, Nowecki Z, et al. 2023.. Abstract GS3-02: GS3-02 camizestrant, a next generation oral SERD versus fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. . Cancer Res. 83:(5 Suppl.):GS3-02
    [Google Scholar]
  22. 22.
    Robertson J, Gogitidze T, Katashvili Z, et al. 2024.. Abstract RF01-01: SERENA-3: a randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer. . Cancer Res. 84:(9 Suppl.):RF01-01
    [Google Scholar]
  23. 23.
    Jhaveri KL, Bellet M, Turner NC, et al. 2024.. Phase Ia/b study of giredestrant ± palbociclib and ± luteinizing hormone-releasing hormone agonists in estrogen receptor–positive, HER2-negative, locally advanced/metastatic breast cancer. . Clin. Cancer Res. 30:(4):75466
    [Google Scholar]
  24. 24.
    Jimenez MM, Lim E, Gregor MCM, et al. 2022.. 211MO Giredestrant (GDC-9545) versus physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. . Ann. Oncol. 33:(Suppl. 7):S63334
    [Google Scholar]
  25. 25.
    Lim E, Chavez M, Bardia A, et al. 2023.. Abstract PD13-04: PD13-04 exploratory subgroup and biomarker analyses of acelERA breast cancer: phase II study of giredestrant (GDC-9545) versus physician's choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer. . Cancer Res. 83:(5 Suppl.):PD13-04
    [Google Scholar]
  26. 26.
    Lim E, Jhaveri KL, Perez-Fidalgo JA, et al. 2020.. A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. . J. Clin. Oncol. 38:(15 Suppl.):1023
    [Google Scholar]
  27. 27.
    Hurvitz SA, Bardia A, Quiroga V, et al. 2023.. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA breast cancer): an open-label, randomised, controlled, phase 2 study. . Lancet Oncol. 24:(9):102941
    [Google Scholar]
  28. 28.
    Bhagwat SV, Zhao B, Shen W, et al. 2021.. Abstract 1236: preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). . Cancer Res. 81:(13 Suppl.):1236
    [Google Scholar]
  29. 29.
    Jhaveri KL, Jeselsohn R, Lim E, et al. 2022.. A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): monotherapy results from EMBER. . J. Clin. Oncol. 40:(16 Suppl.):1021
    [Google Scholar]
  30. 30.
    Jhaveri K, Wang H-C, Ma C, et al. 2023.. Abstract PD13-12: PD13-12 imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: results from the phase 1a/b EMBER study. . Cancer Res. 83:(5 Suppl.):PD13-12
    [Google Scholar]
  31. 31.
    Neven P, Stahl N, Losada MJV, et al. 2023.. 273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): final analysis from EMBER-2. . Ann. Oncol. 34:(Suppl. 2):S29293
    [Google Scholar]
  32. 32.
    Bardia A, Chandarlapaty S, Linden HM, et al. 2022.. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. . Nat. Commun. 13:(1):4116
    [Google Scholar]
  33. 33.
    Tolaney SM, Chan A, Petrakova K, et al. 2023.. AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. . J. Clin. Oncol. 41:(24):401424
    [Google Scholar]
  34. 34.
    Sanofi. 2022.. Sanofi provides update on amcenestrant clinical development program. Press release, Aug. 17. https://www.sanofi.com/en/media-room/press-releases/2022/2022-08-17-05-30-00-2499668
    [Google Scholar]
  35. 35.
    Maglakelidze M, Bulat I, Ryspayeva D, et al. 2021.. Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: phase 1 results. . J. Clin. Oncol. 39:(15 Suppl.):1063
    [Google Scholar]
  36. 36.
    Osborne C, Richards DA, Wilks ST, et al. 2021.. Abstract PS11-26: a phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer. . Cancer Res. 81:(4 Suppl.):PS11-26
    [Google Scholar]
  37. 37.
    Guo S, Zhang C, Bratton M, et al. 2018.. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. . Oncotarget 9:(6):692437
    [Google Scholar]
  38. 38.
    Hodges-Gallagher L, Sun R, Myles DC, et al. 2021.. Abstract PS18-16: The complete estrogen receptor antagonist OP-1250 shrinks tumors in xenograft models and has favorable preclinical pharmacokinetic attributes. . Cancer Res. 81:(4 Suppl.):PS18-16
    [Google Scholar]
  39. 39.
    Hamilton E, Meisel J, Alemany C, et al. 2022.. Phase 1b results from OP-1250–001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). . Eur. J. Cancer 174:(Suppl. 1):S36
    [Google Scholar]
  40. 40.
    Borges VF, Chan A, Lin NU, et al. 2023.. A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2−) breast cancer. . J. Clin. Oncol. 41:(16 Suppl.):TPS1127
    [Google Scholar]
  41. 41.
    Schott AF, Hurvitz S, Ma C, et al. 2023.. Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. . Cancer Res. 83:(5 Suppl.):GS3-03
    [Google Scholar]
  42. 42.
    Campone M, Ma CX, De Laurentiis M, et al. 2023.. VERITAC-2: a global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, versus fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. . J. Clin. Oncol. 41:(16 Suppl.):TPS1122
    [Google Scholar]
  43. 43.
    Hurvitz SA, Schott A, Ma CX, et al. 2023.. 205P VERITAC update: phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. . ESMO Open 8:(1, Suppl. 4):101394
    [Google Scholar]
  44. 44.
    Hamilton EP, Wang JS, Pluard T, et al. 2022.. Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer—a phase II study. . Cancer Res. 82:(4 Suppl.):P117-10
    [Google Scholar]
  45. 45.
    Hamilton EP, Wang JS, Pluard TJ, et al. 2021.. Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. . J. Clin. Oncol. 39:(15 Suppl.):1018
    [Google Scholar]
  46. 46.
    Parisian AD, Barratt SA, Hodges-Gallagher L, et al. 2024.. Palazestrant (OP-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant ER-positive breast cancer models as monotherapy and in combination. . Mol. Cancer Ther. 23:(3):285300
    [Google Scholar]
  47. 47.
    Goetz MP, Bagegni NA, Batist G, et al. 2023.. Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. . Ann. Oncol. 34:(12):114151
    [Google Scholar]
  48. 48.
    Liang J, Ong C, Giltnane J, et al. 2024.. Abstract PS17-01: key drivers of therapeutic response and resistance to giredestrant from GO39932: a phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. . Cancer Res. 84:(9 Suppl.):PS17-01
    [Google Scholar]
  49. 49.
    Turner NC, Kingston B, Kilburn LS, . 2020.. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. . Lancet Oncol. 21:(10):1296308
    [Google Scholar]
/content/journals/10.1146/annurev-med-052423-122001
Loading
/content/journals/10.1146/annurev-med-052423-122001
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error